Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Modern for the development of candidates for a vaccine against seasonal flu, HIV

Modern for the development of candidates for a vaccine against seasonal flu, HIV



Shares of Moderna Inc. MRNA,
+ 3.92%
rose 1.3% in trading markets on Monday after the company said it plans to launch new development programs using its mRNA technology, which will focus on developing vaccines for seasonal flu, HIV and the Nipah virus. This follows the success of his mRNA COVID-19 vaccine, which is one of two vaccines that have been approved so far by the CEO. combinations that fight influenza, COVID-19, RSV and human metapneumovirus. “The uniquely challenging 2020 for the whole society turned out to be an extraordinary period of proof of the concept of Modern,”

; CEO Stefan Bansel said in a news release. As part of its corporate update, Moderna said it had about $ 5.2 billion in cash as of Dec. 31, compared to $ 1.2 billion in cash it had at the same time a year ago, and expects to generate at least $ 11.7 billion in revenue in 2021 for its COVID-19 vaccine based on preliminary purchase agreements. Shares of Moderna have jumped 489.1% in the last year, while the S&P 500 SPX,
-0.53%
is 19.7%.


Source link